CAMBRIDGE, UK, July 23, 2026
AstraZeneca has secured European Commission approval for Etcamah (camizestrant) in combination with a CDK4/6 inhibitor as a first-line treatment for adult patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer whose tumors develop an ESR1 mutation during endocrine therapy without disease progression. The approval marks a significant advancement in precision oncology, making Etcamah the first and only next-generation oral selective estrogen receptor degrader (SERD) approved in this setting and the only option compatible with all widely approved CDK4/6 inhibitors. The decision is based on the landmark SERENA-6 Phase III trial, which demonstrated a 56% reduction in the risk of disease progression or death compared with standard endocrine therapy, offering patients an earlier opportunity to overcome endocrine resistance before disease progression occurs.
SERENA-6 Trial Delivers Landmark Progression-Free Survival Results
The European Commission approval follows a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) and is supported by compelling data from the pivotal SERENA-6 Phase III trial. In the planned interim analysis, patients receiving Etcamah combined with a CDK4/6 inhibitor achieved a median progression-free survival (PFS) of 16.0 months, compared with 9.2 months for patients continuing treatment with an aromatase inhibitor plus a CDK4/6 inhibitor. This translated into a 56% reduction in disease progression or death, representing one of the most significant advances in first-line hormone receptor-positive breast cancer treatment in recent years. The study also demonstrated meaningful improvements in time to second disease progression (PFS2) while maintaining a favorable safety profile with no new safety concerns and low treatment discontinuation rates. These findings reinforce the role of precision medicine in identifying resistance mechanisms early and adjusting treatment before clinical progression occurs.
ctDNA Monitoring Introduces a New Precision Oncology Strategy
A defining feature of the SERENA-6 study is its innovative use of circulating tumor DNA (ctDNA) monitoring, making it the first global registrational Phase III trial to guide treatment changes based on the emergence of ESR1 mutations before disease progression. Patients underwent routine blood-based ctDNA testing every two to three months, allowing clinicians to detect endocrine resistance early and transition eligible patients from aromatase inhibitor therapy to Etcamah while continuing the same CDK4/6 inhibitor. Approximately 30% of patients receiving first-line endocrine therapy develop ESR1 mutations before disease progression, making early detection increasingly important for improving long-term outcomes. Experts believe this strategy could redefine treatment pathways for hormone receptor-positive metastatic breast cancer by integrating molecular monitoring into routine clinical practice and enabling more personalized therapeutic decisions before resistance significantly impacts patient survival.
Advertisement
AstraZeneca Strengthens Its Breast Cancer Innovation Pipeline
The approval represents another milestone in AstraZeneca’s oncology portfolio, with Etcamah becoming the company’s 11th new medicine expected to launch by 2030. The therapy is already approved in Japan, the United Arab Emirates, and Saudi Arabia, while regulatory reviews continue in several other regions, including the United States. As a potent oral SERD and complete estrogen receptor antagonist, Etcamah expands AstraZeneca’s comprehensive breast cancer portfolio, complementing therapies such as Enhertu, Truqap, Datroway, Faslodex, Lynparza, and Zoladex. With breast cancer remaining one of the world’s leading causes of cancer-related mortality, this latest approval reinforces AstraZeneca’s commitment to advancing targeted oncology therapies, improving survival outcomes, and expanding precision treatment options for patients with advanced hormone receptor-positive disease.
Source: AstraZeneca press release
